Cryosite Ltd Total Assets

Latest as of December 2025: AU$26.55 Million AUD ≈ $18.78 Million USD

Cryosite Ltd total assets. Based on the latest financial reports, Cryosite Ltd (CTE) holds total assets worth AU$26.55 Million AUD (≈ $18.78 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CTE company net worth for the company's overall valuation and market capitalisation.

Total Assets of Cryosite Ltd (2001–2025)

Total assets of Cryosite Ltd from 2001 to 2025. This chart illustrates how Cryosite Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Cryosite Ltd for real-time trading data and today's change.

Cryosite Ltd - Asset Composition Analysis

Cryosite Ltd Total Assets Breakdown (June 2025)

Cryosite Ltd total assets breakdown as of June 2025. Cryosite Ltd's total assets of AU$26.55 Million consist of 45.6% current assets and 54.4% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 26.0%
Accounts Receivable AU$2.29 Million 11.7%
Inventory AU$43.00K 0.2%
Property, Plant & Equipment AU$1.42 Million 7.3%
Intangible Assets AU$32.00K 0.2%
Goodwill AU$0.00 0.0%

Asset Composition Trend (2001–2025)

This chart illustrates how Cryosite Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cryosite Ltd (CTE) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Cryosite Ltd's current assets represent 45.6% of total assets in 2025, a decrease from 70.4% in 2001.
  • Cash Position: Cash and equivalents constituted 26.0% of total assets in 2025, down from 68.0% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
  • Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.

Cryosite Ltd Competitors by Total Assets

Key competitors of Cryosite Ltd based on total assets are shown below.

Company Country Total Assets
Revvity Inc.
NYSE:RVTY
USA $12.00 Billion
Wuhan Thalys Med Tech Co Ltd
SHG:603716
China CN¥1.59 Billion
JOONGANG DNM Co.Ltd
KQ:051980
Korea ₩121.79 Billion
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
China CN¥984.02 Million
Krsnaa Diagnostics Limited
NSE:KRSNAA
India Rs15.07 Billion
Sonic Healthcare Ltd
AU:SHL
Australia AU$16.78 Billion
Integral Diagnostics Ltd
AU:IDX
Australia AU$1.43 Billion
Australian Clinical Labs Ltd
AU:ACL
Australia AU$562.50 Million

Cryosite Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.49 1.78 1.62
Quick Ratio 0.48 1.77 1.61
Cash Ratio 0.00 0.00 1.27
Working Capital AU$-5.73 Million AU$3.40 Million AU$2.11 Million

Cryosite Ltd - Advanced Valuation Insights

This section examines the relationship between Cryosite Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 16.23
Latest Market Cap to Assets Ratio 2.16
Asset Growth Rate (YoY) -1.3%
Total Assets AU$19.46 Million
Market Capitalization $42.13 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Cryosite Ltd's assets at a significant premium (2.16x), suggesting investors see substantial growth potential or unique competitive advantages.

Slight Asset Contraction: Cryosite Ltd's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Cryosite Ltd (2001–2025)

The table below shows the annual total assets of Cryosite Ltd from 2001 to 2025.

Year Total Assets Change
2025-06-30 AU$19.46 Million
≈ $13.77 Million
-1.26%
2024-06-30 AU$19.71 Million
≈ $13.95 Million
-12.96%
2023-06-30 AU$22.65 Million
≈ $16.02 Million
+5.32%
2022-06-30 AU$21.50 Million
≈ $15.21 Million
-2.23%
2021-06-30 AU$21.99 Million
≈ $15.56 Million
-6.42%
2020-06-30 AU$23.50 Million
≈ $16.63 Million
+1.42%
2019-06-30 AU$23.17 Million
≈ $16.40 Million
+199.24%
2018-06-30 AU$7.74 Million
≈ $5.48 Million
-21.20%
2017-06-30 AU$9.83 Million
≈ $6.95 Million
+1.76%
2016-06-30 AU$9.66 Million
≈ $6.83 Million
+5.86%
2015-06-30 AU$9.12 Million
≈ $6.45 Million
-18.49%
2014-06-30 AU$11.19 Million
≈ $7.92 Million
-1.49%
2013-06-30 AU$11.36 Million
≈ $8.04 Million
+16.29%
2012-06-30 AU$9.77 Million
≈ $6.91 Million
+13.28%
2011-06-30 AU$8.63 Million
≈ $6.10 Million
+12.27%
2010-06-30 AU$7.68 Million
≈ $5.44 Million
+4.46%
2009-06-30 AU$7.35 Million
≈ $5.20 Million
+1.46%
2008-06-30 AU$7.25 Million
≈ $5.13 Million
+13.30%
2007-06-30 AU$6.40 Million
≈ $4.53 Million
+25.10%
2006-06-30 AU$5.11 Million
≈ $3.62 Million
+9.71%
2005-06-30 AU$4.66 Million
≈ $3.30 Million
+5.87%
2004-06-30 AU$4.40 Million
≈ $3.12 Million
+24.92%
2003-06-30 AU$3.52 Million
≈ $2.49 Million
-19.14%
2002-06-30 AU$4.36 Million
≈ $3.08 Million
+7.68%
2001-06-30 AU$4.05 Million
≈ $2.86 Million
--

About Cryosite Ltd

AU:CTE Australia Diagnostics & Research
Market Cap
$42.13 Million
AU$59.55 Million AUD
Market Cap Rank
#22273 Global
#784 in Australia
Share Price
AU$1.22
Change (1 day)
+0.00%
52-Week Range
AU$1.00 - AU$1.30
All Time High
AU$1.30
About

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more